• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    A novel anthracycline antibiotic complex designated herein as baumycin complex is produced by fermentation of a baumycin-producing strain of Streptomyces, e.g. Streptomyces coeruleorubidus ME 130-A4 (FERM-P3540, ATCC 31276). The complex and four bioactive components thereof designated baumycin A1, A2, B1 and B2 are useful as antibacterial and antitumor agents.
    公开号:SU867318A3
    申请号:SU772491882
    申请日:1977-05-30
    公开日:1981-09-23
    发明作者:Умезава Хамао；Такеючи Томио；Хамада Маса；Исизука Масааки；Наканава Хироси；Оки Точиказу；Инуи Тайдзи
    申请人:Зайданходзин Бисейбуцу Кагаку Кенкиюкаи (Фирма)；
    IPC主号:
    专利说明:

    (54) METHOD FOR OBTAINING BOOMICINE QUARTER
    Shtalai has the following cultural and morphological features. Under the microscope, open spirits & hook and hook forms are observed, which are significantly developed from the expanded substrate of the mycelium. The rings are absent, the chain of spores has a moderate length with the number of spores greater than 10. The size of spores is 0.6–0.8 µm X 1.0 1, 2 µm, the surface of the spores is covered with spikes. .. Glycerin-asparaginovy agar. Filaments from pale reddish yellow to dark red. Aerial mycelium is in a gray color. The soluble pi is light reddish yellow. Saccharose-nitrate agar. Sustained mycelium - filaments pale reddish yellow, pale red to dark red. Aerial mycelium slightly white. Soluble pigment - slightly dark red. - Glucose-aspartic agar. The threads are colorless, pale yellow to pale orange. Aerial mycelium is off-white to light gray, becoming abundant after 14 days of incubation. Soluble pigment is missing. Tyrosine agar. Threads are greyish red brown. Aerial mycelium from blue-white to light blue. Dark brown soluble pigment. Nutritional Balance The threads are yellowish brown. Aerial mycelium is white. Soluble pigment brown. Yeast extract agar and malt agar - dull orange threads Aerial mycelium light gray. Soluble pigment is slightly brown. Agar with oat flour. Threads from colorless to pale orange. Aerial mycelium is light gray .. There is no soluble pigment. . . Glycerin-nitrate agar. Threads from colorless to pale orange. Aerial mycelium from white to light gray. Soluble pigment absent. vuit. Unclean milk is pale yellow to dark brown, yellowish brown to pale red, and mycelium is slightly white. Soluble pigment brown. The physiological properties of the strain. The optimal growth temperature from 30 to. Gelatinu liquefies. Collapse is small hydrolyzes. Milk peptonizes and coagulates at 37 ° C. Melanin forms. It grows well with glucose, eL-arabinose, D-xylose, sucrose, rattinose, D-fructose, 1, -ramnose, mannitol. Dilutes calcium sulphate. Baumicin is obtained by cultivating the strain in a standard aqueous nutrient medium containing sources of carbon, nitrogen, and inorganic salts; glycerol, glucose, starch / dextrin, sucrose, maltoZU, oils, and fats are used as carbon sources. As nitrogen sources, soybeans, yeast extract, peptone, cotton seed powder, dry yeast, grain soaking liquid, or inorganic salts, such as ammonium sulfate, sodium nitrate or ammonium chloride, are used from inorganic salts, sodium chloride, potassium chloride or phosphates, if necessary, add traces of metals and defoaming agents, such as adecanol or silicone. The preferred cultivation temperature is 25-30 ° C. The maximum yield of bamycin in culture broth is reached in 3-7 days. To remove the baumycin complex, the broth is filtered and the filtrate is then subjected to extraction of immiscible water with an organic solvent, such as ethyl acetate, butyl acetate, chloroform or n-butyl alcohol. Bamycin in mycelium is extracted with chloroform, acetone, n-butanol, methanol, ethanol, ethyl acetate or an aqueous solution of an organic or inorganic acid, such as hydrochloric acid, sulfuric acid, or acetic acid. After concentration and vacuum, the baumycin extracts are re-extracted with organic solvent, immiscible with water at pH 7-9, and then baumitsin is dissolved in an acidic aqueous medium at pH 4. Then baumitsin in an acidic aqueous solution is subjected to repeated extraction with an organic solvent m after adjusting the pH to a weakly alkaline value. Bumidine can be extracted from the culture liquid by column chromatography using such adsorbents as activated carbon, aluminum gel, silicic acid or modified Sephadex LN-20 brand dextran, countercurrent distribution or liquid chromatography using organic solvents. The active extracts obtained in this way are concentrated under reduced pressure and the result is a crude red powder of the baumycin complex. For the preparation of the Baumic components A, AO, B, and B, additional purification and separation on a column are carried out using adsorbents such as silicic acid, modified dextrans, weakly acid-exchange resins or activated carbon, as well as liquid chromatography with countercurrent distribution and
    Using acceptable organic solvents.
    The active eluates are separated, concentrated under reduced pressure, and the baumycin components are individually purified by chromatography on Sepha. The physicochemical properties of baumidex d.H-20. After concentration of 5 qin, R., Pi, B, and B are presented in the active eluates by recrystallization.
    4., l and 1
    Bamycin.
    AppearanceWalls Healing Amorphous Red Powder
    Elementary with N N O C N N O analysis. Found 59, 85 6.65 2.04 29.83 60.27 6.72 2.31 29.52
    theoretical 60.61 6.43 2.08 30.88 60.61 6.43 2.08 30.88
    Empirical - g and MP
    Formula 3 "i3
    Molecular / T
    Melting point, c182-185185-189
    Specific rotation Gs1.3 ° + 150 + 135 (СНС1з-с 0.1) Solubility RJ values С: М: В 7: ЗгЗ С: M: F 90: 10: 1 С: М: А 80: 20: 4 Reactions
    Baumycin Components A, A-,
    B and B in purified
    crystalline form. Soluble in acidic water, dimethyl sulfoxide, methyl cellosolve, methyl alcohol, ethyl alcohol, n-propanol, n-butanol, ethyl acetate, butyl acetate, acetone, methyl ethyl He, methylene chloride and chloroform. Insoluble in water, n-hexane, cyclohexane and petroleum ether- .- .. The acidic aqueous and methanol solution is red, and turns into a reddish-purple in the alkaline state. Baumitzins A and Aj give a positive ningkdrinovuyu reaction, and do not restore the solution fechling.
    Wamycin
    234.5 (452); 252.5 (327); 289 (120) 478 (127) 497 (128); 532 (76)
    234.5 (459); 252.5 (326);
    O, IN HC1 - MeOH 289 (121); 479 (133); 497 (133); 532 (78)
    250.5 (416); 350 (83);
    B O, IN NaOH-MeOH 558 (164); 597 (152)
    Bamycin Appearance Weak alkaline
    Elementary analize
    Empirical formula
    Molecular weight
    Point melting 181-189, ° C
    Specific rotation + 170 AJ Solubility
    Continuation of table 1
    234.5 (427); 252.5 (311); 289 (108); 478 (125); 497 (128); 532 (84)
    234.5 (447); 252.5 (311); 289 (111); 478 (131); 497 (131); 532 (70)
    250.5 (421); 350 (80); 558 (170); 596 (164)
    AT
    H "41 0-14
    687.7
    197-201
    +170 (MeOH 1: 1; C 0.1) Soluble in acidic water, methyl cellosolve, methanol, ethanol, n-propanol, n-butanol. It is insoluble in water, ethyl acetate, acetone, methylene chloride, chloroform, carbon tetrachloride, benzene, toluene, ethyl ether, and n-hectare sane, besides baumitsin Ba. water soluble amorphous red powder
    Staph.aureus
    Fp A209P1,56
    Staph.aureus Smith 0.78
    Continuation of table 1
    100 50
    50 50
    3.12 1.56 BamycinAA R values C: M 10; 10.070.01 C: M: B 7; 3: 30,390,14 C: MgP 90: 10: 10,180,10 C: Mift 80: 20: 40,640.30 Reaction The acidic aqueous and methanolic solution is red, and in an alkaline medium it becomes reddish-purple. Bamycin B and Bj. gives a positive ninhydrin reaction, and does not restore the Fehling solution. Bamycin. , -. --I UV and visible spectrum 234.5 (552); 253 (385); 234 (575); 252 (414); absorption And maxi-290 (132); 476 (179); 290 (130); 478 (176); Minimum () 495 (181); 530 (101) 495 (183); 530 (120) to MeOH in 0.1N HC1-MeOH234 (580); 253 (397); 234 (616); 253 (419); 290 (140); 479 (182); 290 (145); 476 (195); .495 (184); 530 (100) 494 (191); 529 (105) O, IN NaOH-MeOH 251 (453); 350 (65); 251 (499); 350 (74); 556 (206); 594 (195) 556 (231); 594 (218). Bamycins A and A., B. and B of ow -45 Bau-mycins A, A, G and B, j possess stereoisomers with respect to the antimicrobial activity of another friend and can easily be distinguished by a wide range of microorganisms with different physical properties - they are different. melting points, specific rotation, R coefficient for a thin layer chro-50 Antimicrobial spectrum of Baumi-matography, NMR peaks. New, Aji, B and Bj are listed in Table 2. Minimal suppressive concentrations,. The test organism b / ml baumitsin baumitsin baumitsin baumitsin Table 2 A I AA ..
    eleven
    86731812
    Continuation of Table 2 Acute toxicity. The intraperitoneal ci D values of antibiotics are as follows: “iD 50 (mg / kg) 1.5-2.5 baumitsnn And baumitsin baumitsin B 75-100 baumitsin B salt-forming reagents, as well as non-toxic complexes with deoxyribonucleic acid. Thus, adduct salts of acids obtained with such pharmaceutically acceptable acids as seed, phosphoric, hydrochloric, acetic, .. propionic, and acids of oleic, palmitic, citric, succinic, tartaric, glutamic, pantothenic, etc. ., non-toxic complexes with deoxyribonucleic acid can be used in the same way as baumycin compounds. Salts are obtained by isolation, purified and formulated by methods commonly used in the preparation of salts for antibiotics. Forms for intraperitoneal administration include sterile interfering or non-aqueous solutions, suspensions or emulsions. They can also be manufactured in the form of sterile solid formulations that can be dissolved in sterile water, physiological OR or some other sterile sprayable media immediately before use. The preferred amounts of the baumycin antibiotic used must be varied depending on the compound used, the type of position, the treatment regimen and the type of disease. Usually, baumycin antibiotics inject animals in the abdomen, intravenously, subcutaneously, or. locally and to a man intrabyally or locally. Many factors should be taken into account that MODIFY the action of the drug, sprish age, body weight, sex,, introduction, treatment regimen, rate of administration, condition of the patient, combination of drugs, sensitivity and severity of the disease. Administration can be carried out continuously, periodically, with the use of tolerant doses. The optimal quantities used for this list of conditions can be determined by those skilled in the art using standard test methods. When using baumicin compositions as an antimicrobial substance, the compositions are usually administered so that the concentration of the active ingredient is the minimum inhibitory concentration for the particular type of organism being treated. Example 1. A nutrient medium of the following composition is prepared, wt. -%: Potato starch1 Glucose1 Soybean Powder1.5 K, 2.HP046.1 - MaSO. 7H “00.1 MgS04 7H ,, 0 NaCI 0.3 Mineral 0.125 (pH 7.4) - CuS04-SH d ResOd. 7N.O mnststs- 4n;: about Zn50. . 0.8 g in 500 ml of water. 50 ml of this medium are sterilized at 120 ° C for 15 minutes in a 500 ml flask, which is seeded with oblique culture of St reptomyces coeru teorubldus ME 130-A4 agar using a platinum loop. Incubation was performed for 72 hours at 28 ° C on a rotating stirrer (230 rpm). The medium is used as a seed. Prepare 7 liters of the following medium, and 50 ml of the medium portion, injected and sterilized in a 500 ml flask, are aseptically seeded with 1 MP of the indicated culture. The fermentation is carried out for 7 days per rotation of the stirrer (230 rpm). Receive, wt.%: Sucrose4 Soy bean powder 2.5 Nate0.25 Calcium carbonate 0.32 Mineral 0.125 (pH 7.4) CuS04-5H minergsh 25 g MnS04.-4HrtO1.25 g, 5 g in 500 ml water. The prepared culture broth is filtered to separate the culture filament and mycelium. The filtrate is extracted three times with 1/5 volume of chloroform. Mycelium is extracted three times with 2 liters of acetone per 1 kg of filter cake, and the resulting acetone extract is concentrated to half the volume under reduced pressure. Concentration; extracted three times with 2 l of chloroform, combined with a :: lorum solution, which is obtained from the filtrate to: / lute, and concentrated to dryness under reduced pressure. 10 g of the oily substance is dissolved in 50 ml of chloroform, and, when 300 ml of n-hexane are added, the cage is centrifuged for 3 minutes at 3000 rpm to remove the pure soluble substances.
    n-hexane. The precipitate obtained (1.4 g) is dissolved in 100 ml of chloroform and extracted three times with 150 ml of 0.01 M acetic acid to obtain the substances soluble in acid. To the extract was added 2 M tris-oxyamino-methane solution, adjusted to pH 8.5, and then the solution was extracted three times with 100 ml of chloroform. The result is 230 mg of red raw powder (baumitsinovogo complex) of the chloroform layer by concentration to dryness under reduced pressure.
    EXAMPLE 2 The crude powder obtained in Example 1 (230 mg) was dissolved in 2 ml of a mixture of chloroform and methyl alcohol (10: 1), injected into a column 65 cm long and 8 cm in diameter, filled with 80 g of silicic acid, and washed with a mixture of chloroform and methyl alcohol (10: 1). First, the baumycin A-fraction is eluted, and then the AJ, B, and B baumycins are successively used, respectively, as an eluent solution of a mixture of 8: 1, 5: 1 and 2: 1 chloroform with methyl alcohol.
    After each active fraction is collected separately and concentrated to dryness under reduced pressure, each such fraction is introduced into a column 25 cm long and 1.8 cm in diameter, filled with Sephadex eLH-20, r washed with a 3: 1 mixture of toluene and methyl alcohol
    After concentrating each fraction obtained by adding n-hexane to the concentrate, 10 mg of baumycin A, 18 mg of baumycin A 2, 3 mg of baumycin B and 1 mg of baumycin B are obtained as red powders.
    Example 3. Preparing a nutrient medium of the following composition, wt.%: Potato starch 2 Glucose2
    Yeast
    extract0,5
    Chloride
    sodium - 0.25
    Carbonate
    calcium 0.32
    Soyeva flour 2
    Mineral 0,2
    (pH 7.4)
    - the same as in example 1. Prepare 8 liters of this medium, which is distributed in 50 ml portions of 500 ml flasks, sterilized for 15 minutes and inoculated with 1 ml of seed and Streptomyce peuceticus subsp.carneus ATCC21354, prepared in accordance with the method of example1. The fermentation is carried out on a rotating stirrer at 28 ° C for 6 days. The culture broth is filtered to separate the mycelium from the culture filtrate. Extraction is carried out with chloroform and acetone, as in Example-1, and 10 g of an oily product are obtained. The latter is dissolved in 100 MP of methyl alcohol and n-hexane-soluble substances by adding 100 ml of n-hexane, and 1.2 g of precipitate is obtained after removal. The red precipitate is dissolved in 100 ml of chloroform and extracted with 600 ml of sodium acetate buffer (pH 3.0) to obtain a water-soluble substance.
    After addition of 0.5 M of ethylenediaminetetraacetic acid to the extract in an amount necessary to obtain a solution of 0.01 M, the pH is adjusted to a value of 8, for which 4 M of sodium hydrochloride is added.
    The active components of the aqueous solution are extracted four times with 200 ml of chloroform, and then extracted twice with 500 ml of n-butyl alcohol. The resulting chloroform and n-butanol layers are concentrated separately under reduced pressure and receive 200 mg of red powder, which is mainly baumycin c. This crude powder was dissolved in 5 ml of chloroform-methyl alcohol, injected into a 23 cm long column and 3.0 cm in diameter, filled with 80 g of silicic acid, and washed with a mixture of 20: 1 chloroform and global alcohol. Waumicin B2 was sequenced with mixtures 5: 1 and 2: 1 chloroform and methyl alcohol. The fractions of bamycins Bf and B / 2 are concentrated separately under reduced pressure, resulting in 50% of which is obtained 50 mg of baumycin B and 8 mg of baumycin B. With this method, very small amounts of baumycin A and AZ are obtained.
    0
    Example 4. Preparing a nutrient medium of the following composition, wt.%:
    Potato
    one
    starch
    one
    Glucose
    five
    1.5
    "Soy powder
    0.1
    0.1
    MgS04-TNLO
    NaCI
    0.3
    Mineral
    0.125
    0
    (pH 7.4)
    -CuS04-
    2.8 g
    FeS04-7H 0
    0.4 g
    MPS1
    3.2 g
    2p50d.
    0.8 g
    in 500 ml of water.
    five
    50 ml of this medium are sterilized at 120 ° C for 15 minutes in a 500 ml flask, which is inoculated with a platinum loop of a culture of Streptomyces peuceticus subsp.caestus NRRL-B-5337 grown on oblique agar.
    权利要求:
    Claims (2)
    [1]
    Incubation is continued for 72 hours with a rotary shaker (230 rpm). Prepare 7 l of the described medium and 50 ml of the medium in a sterilized 500 MP flask, aseptically inoculate 1 ml of the indicated seed culture. For 7 days on a rotary shaker (230 rpm), fermentation is carried out at, wt%: Sucrose Soy protein Carbonate 0.32 calcium 0.25 Mineral 0.125 (pH 7.4) -CuS04 1.25 g MnClij 1 , 25 g of ZnSO.) 5 g of 12.5 g in 500 ml of water. The resulting culture broth is filtered off in order to separate the culture filtrate and mycelium, the filtrate is extracted three times with 1/5 volume of chloroform. The mycelium is extracted three times with 2 l of acetone per 1 kg of pellet, and the resulting acetone extract is concentrated to half the volume under reduced pressure. The resulting concentrate is extracted three times with 2 liters of chloroform, combined with a chloroform solution that is semi-finished for the culture filtrate, and concentrated to dryness under reduced pressure, 10 g of the oily substance obtained is dissolved in 50 ml of chloroform, and the precipitate that formed upon the addition of 300 ml of n -hexane, centrifuged for 5 minutes at 3000 rpm to remove impurities soluble in n-hexane. The resulting residue (1.8 g) is dissolved in 100 ml of chlorine form and extracted three times with 200 ml of 0.01 M acetic acid to obtain an acid-soluble substance. To this extract was added a 2 M solution of tris oxy-aminomethane to adjust the pH to 8.5; and then this solution is extracted three times with 100 ml of chloroform. As a result, 185 g of red n purified powder (baumi- cin complex) from a layer of chloroform are obtained after co-centering it to dryness under reduced pressure. 185 g of the obtained crude powder is dissolved in 2 MP Zsloroform-methanol (10: 1) mixture, introduced into a 65 cm long column and 8 cm in diameter, filled with 80 g of silicic acid, and washed with a mixture of chloroform-methanol (10: 1 ). First, the fraction of baumicin A is eluted, then successively, baumycin A, 2, B and (And, respectively, chloroform-methanol (8: 1, 5: 1 and 2: 1) is used as eluent. Each active fraction is collected separately and concentrated to dryness under reduced pressure, each of these fractions was introduced into a column 25 cm long and 1.8 cm into a diameter filled with Sephadex J, H-20 and washed with a toluene-methanol (3: 1) mixture. After concentrating each fraction ID, obtained by adding n-hexane to the concentrate ") m, get red powders: 11 mg of baumycin A, 10 mg of baou Mycin A, 7 mg of bamycin B and 3 mg of bamycin 3. Example 5. The nutrient medium of the following composition is obtained, wt.% Potato starch Glucose Soy powder K2HPO4 MgS04-TH / jO Mineral (pH 7.4) -CuS04. FeS04. Mncii- 4n: about ZnS04. MP water MP of this medium is sterilized with a 500 ml flask which is inoculated with a platinum loop of Streptotnyces peucetlcus NRRL-B-3826 culture on oblique agar for 15 minutes. Incubation is carried out for 72 hours at 28 seconds on a rotary shaker (230 rpm). 7 l of the described medium and 50 ml of medium distributed and sterilized in a 500 ml flask are prepared, aseptically inoculated with 1 ml of the indicated culture. The enzyme is carried out for 7 days on a rotor shaker (230 rpm). Half, wt.%: Sucrose Soy protein Carbonate 0.32 calcium Mineral 0.125 (pH 7.4) -CuS04-5HiO 1.25 g 1.25 g MnC1.2. - 4H „0 ZnS047 0 12.5 g 500 ml water. The cultured broth thus obtained is filtered to separate the culture filtrate and myeli. The filtrate is extracted three times / 5 volume of chloroform. The mycelium is extracted three times with 2 l of acetone per 1 kg of the cake, and the resulting acetone extract is concentrated to half volume under reduced pressure .. The concentrate is extracted three times with l chloroform / combined with a solution of chloroform, which is obtained from the culture effluent, and concentrated by drying at a reduced pressure. 10 g of the oily substance obtained are dissolved in 50 ml of chloroform and the sediment formed by adding 300 ml of n-hexane is centrifuged for 5 minutes at a speed of 300 vol. rpm to remove n-hexane soluble impurities. The resulting residue (1.2 g) is dissolved in 100 ml of chloroform and extracted three times with 150 ml of 0.01 M acetic acid to obtain acid-soluble substances. To this extract was added a 2 M solution of tris-oxyaminomethane to adjust the pH to 8.5, and then the resulting solution was extracted three times with 100 ml of chloroform. Thus, 97 mg of an unpure red powder (baumicin complex) from a chloroform layer is obtained by concentration to dryness under reduced pressure. The crude product thus obtained (97 mg) is dissolved in 2 ml of chloroform-methanol (10: 1) and introduced into a column 65 cm long and 8 cm in diameter, filled with 60 g of silicic acid, and washed with a mixture of chloroform-methanol (10: 1 ). At the beginning / elute the fraction A, then successively the fractions of baumycin A, B and Bn, using chloroform - methanol (.., 5: 1 and 2: 1) as eluent. After each of the active fractions collected separately and concentrated to dryness under reduced pressure, they are introduced into columns 25 cm long, 1.8 cm in diameter, filled Sephadex dH-20, and washed with a toluene-methanol mixture 3: 1. After concentrating each of the fractions obtained earlier, after adding n-hexane to the concentrates, semi-red powders: 10 mg of baumycin A, 5 m baumucin A / j, 1 mg Baumitsin B and 3 mg Baumycin B,
    [2]
    2. The proposed method allows to obtain anthracycline glycosidic antibiotics of bamycin A and B. Formula of the invention Method of obtaining bamycin A and B of the formula 5 OI oH (Bamycin A) 0 / S (Bamycin B) in which Streptomyces coeruleorubidus ME 130 strain -A4 (ATCC 31276), Streptomyces peucetlcus subsp.carneus ATCC 21354, Streptomyces peuceticus subsp.caestus NRRL-B-5337 or Streptomyces peucetjcus NRRL-B-3826 are cultured under aerobic conditions, with a nutrient, it is used by the same, you must put the line, you should use the same source, you should use the same source, you should use the same source, you will have the same source, you will have the same source, you should use the same source, you will have the same salts, followed by isolation of the target npoj; yKTa, npd need an antibiotic chromatographically section l dissolved in the components A and B and converted into salts.
    类似技术:
    公开号 | 公开日 | 专利标题
    CS207397B2|1981-07-31|Method of preparation of the new anthelmintic compounds
    NL192989C|1998-07-03|Antibiotic, method of preparation and pharmaceutical preparation containing this antibiotic.
    DK170029B1|1995-05-01|Benanomicin compounds and their salts and esters, processes for their preparation, antifungal agents containing them, and their use in the preparation of pharmaceutical preparations
    KR940000759B1|1994-01-29|Novel glycopeptide antibiotics
    SU867318A3|1981-09-23|Method of preparing baumycin a and b
    US4918054A|1990-04-17|Antibiotics called `chloropolysporins B and C`, a process for their preparation, and their therapeutic and veterinary use
    KR100659680B1|2006-12-21|Antibiotic caprazamycins and process for producing the same
    EP0185456A2|1986-06-25|CL-1577D and CL-1577E antibiotic/antitumor compounds, their production and use
    HU179463B|1982-10-28|Process for preparing deoxy-narasin antibiotic complex
    IE62586B1|1995-02-08|Antifungal antibiotics
    DK146342B|1983-09-12|METHOD FOR PREPARING ANTHRACYCLING LYCOSID ANTIBIOTICS DESIGNED MA 144-M1 AND MA 144-M2 OR NOT TOXIC ACID ADDITION SALTS OR COMPLEXES THEREOF WITH DESOXYRIBONUCLEIC ACID
    US5028536A|1991-07-02|Antitumor antibiotic BMY-41339
    EP0253413B1|1993-10-13|New antibiotics called "mureidomycins a, b, c and d" a process for their preparation and their therapeutic use
    EP0545955B1|1995-01-25|Antibiotic ge1655 complex and its factors a, b and c
    EP0472186B1|1996-10-23|Antibiotics AB-023 and process for preparing them
    US4565781A|1986-01-21|Antibiotic, Spicamycin
    US5306496A|1994-04-26|Antibiotics NK374186A, NK374186B, NK374186B3 and NK374186C3, process for producing the same, and use of the same
    KR0173195B1|1999-02-01|It-62-b substance and medical composition containing the same
    US4232006A|1980-11-04|Antibiotic W-10 complex, antibiotic 20561 and antibiotic 20562 as antifungal agents
    US4137224A|1979-01-30|Process for the preparation of antibiotic W-10 complex and for the isolation of antibiotic 20561 and antibiotic 20562 therefrom
    US5086045A|1992-02-04|Antitumor antibiotic
    US4895864A|1990-01-23|Antibiotic TAN-950A, its production and use
    CA2016084A1|1990-11-05|New microbial transformation product
    US5270187A|1993-12-14|Microbial transformation product
    FR2460961A1|1981-01-30|TALLYSOMYCIN DERIVATIVES, PROCESS FOR THEIR PRODUCTION AND MEDICAMENT CONTAINING SAME
    同族专利:
    公开号 | 公开日
    YU134277A|1983-01-21|
    DK233477A|1977-12-01|
    ZA773228B|1978-04-26|
    FR2353564A1|1977-12-30|
    AU2541277A|1978-11-30|
    CH634079A5|1983-01-14|
    YU114385A|1985-10-31|
    US4198480A|1980-04-15|
    SE7706350L|1977-12-01|
    YU114485A|1985-10-31|
    GB1544195A|1979-04-11|
    LU77449A1|1977-12-14|
    SE436043B|1984-11-05|
    AU512372B2|1980-10-09|
    YU43413B|1989-06-30|
    IE45070L|1977-11-30|
    DE2724441A1|1977-12-22|
    BE855098A|1977-11-28|
    GR73592B|1984-03-26|
    YU42643B|1988-10-31|
    YU42641B|1988-10-31|
    US4147778A|1979-04-03|
    FR2353564B1|1983-03-11|
    FI58159C|1980-12-10|
    CA1093998A|1981-01-20|
    DK144569B|1982-03-29|
    DK144569C|1982-09-13|
    FI771686A|1977-12-01|
    YU114585A|1985-10-31|
    IE45070B1|1982-06-16|
    NL7705812A|1977-12-02|
    YU114685A|1985-10-31|
    YU114285A|1985-10-31|
    YU42642B|1988-10-31|
    YU43412B|1989-06-30|
    YU40479B|1986-02-28|
    JPS52148064A|1977-12-08|
    FI58159B|1980-08-29|
    DE2724441C2|1985-10-17|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    GB846130A|1956-03-23|1960-08-24|Ciba Ltd|New antibiotic and derivatives and salts thereof, preparations containing the same and process for the manufacture of these substances|
    US3092550A|1957-10-29|1963-06-04|Ciba Geigy Corp|Antibiotic danubomycin and process for its manufacture|
    CH362490A|1957-10-29|1962-06-15|Ciba Geigy|Process for the production of a new antibiotic|
    FR1533151A|1962-05-18|1968-07-19|Rhone Poulenc Sa|New antibiotic and its preparation|
    US3989598A|1962-05-18|1976-11-02|Rhone-Poulenc S.A.|Antibiotic daunorubicin and its preparation|
    US4012284A|1962-11-16|1977-03-15|Societa' Farmaceutici Italia, S.p.A.|Process of preparation of antibiotic F.I. 1762 derivatives|
    FR1527892A|1967-03-15|1968-06-07|Rhone Poulenc Sa|New process for preparing the antibiotic 13057 r.p.|
    US3803124A|1968-04-12|1974-04-09|Farmaceutici It Soc|Process for the preparation of adriamycin and adriamycinone and adriamycin derivatives|
    US3686163A|1968-05-14|1972-08-22|Farmaceutici Italia|Dihydrodaunomycin antibiotic and derivatives thereof|
    FR1593235A|1968-11-18|1970-05-25|
    US3590026A|1969-01-03|1971-06-29|Phillips Petroleum Co|Recovery of polymers from solution|
    US3864480A|1974-05-06|1975-02-04|Merck & Co Inc|Cinerubin A and B As Antiparasitic Agents|
    US4039663A|1975-03-19|1977-08-02|Societa' Farmaceutici Italia S.P.A.|Daunomycins, process for their uses and intermediates|DK160616C|1979-02-03|1991-09-02|Zaidan Hojin Biseibutsu|PROCEDURE FOR PREPARING ANTHRACYCLINE DERIVATIVES OR ACID ADDITIONAL SALTS THEREOF|
    JPS5648893A|1979-09-07|1981-05-02|Sanraku Inc|Preparation of anthracycline glycoside|
    JPS6217597B2|1979-09-14|1987-04-18|Ishihara Sangyo Kaisha|
    US4439477A|1980-10-30|1984-03-27|Lignotock Verfahrenstechnik Gmbh|Fiber mat for producing a three dimensional molded molding by the dry process|
    JPH0365157B2|1982-07-24|1991-10-09|
    DK356087A|1987-07-09|1989-01-10|Biogal Gyogyszergyar|PROCEDURE FOR ISOLATING AN ANTIBIOTIC|
    JP2779652B2|1988-12-27|1998-07-23|武田薬品工業株式会社|Bioactive substance TAN-1120, its reduced form, their production method and use, and microorganism|
    US4977084A|1989-02-16|1990-12-11|Board Of Trustees Operating Michigan State University|Production, isolation, and identification of novel antifungal compounds|
    GB9727546D0|1997-12-31|1998-03-18|Pharmacia & Upjohn Spa|Anthracycline glycosides|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    JP6381076A|JPS52148064A|1976-05-31|1976-05-31|Antitumors|
    [返回顶部]